Prostate Cancer Xofigo Is A New Drug For Late Stage Prostate Cancer
Prostate Cancer — Xofigo Is A New Drug for Late Stage Prostate Cancer
The drug binds with bone minerals to target the radiation toward bone tumors. In a clinical trial, some 800 men with advanced prostate cancer were randomized to Xofigo or placebo plus best standard of care. In an interim analysis, median survival was roughly 3 months longer with Xofigo than with placebo (14 vs. 11.2 months).
The most frequent adverse effects included gastrointestinal symptoms, peripheral edema, and cytopenias.